ZALDIAR EFFERVESCENS 37,5MG/325 MG TBL EFF 10

What is the maximum co-payment for ZALDIAR EFFERVESCENS?

If the insurance company contributes, the maximum co-payment is 114,42 Kč. The maximum pharmacy price is 131,50 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, but the reimbursement conditions (reporting limit) have not been set.

Does ZALDIAR EFFERVESCENS have a counted co-payment set?

Yes, the medicine has a counted co-payment of 6,00 Kč. Learn more about the protective limit here.

How much does the insurance company pay for one dispensed reimbursed pack?

17,08 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

The medicine has no indication restriction. Its reimbursement is not conditional on a specific diagnosis or clinical condition.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe ZALDIAR EFFERVESCENS?

Prescription is not conditional on a medical specialization.

What is the composition of ZALDIAR EFFERVESCENS?

Paracetamol (325 mg), tramadol-hydrochlorid (37,5 mg), neznámá látka s kódem 10281, kyselina citronová, povidon k 30, hydrogenuhličitan sodný, makrogol 6000, koloidní bezvodý oxid křemičitý, magnesium-stearát, pomerančové aroma, neznámá látka s kódem 3804, sodná sůl sacharinu, oranžová žluť sy. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Which medicines are similar to ZALDIAR EFFERVESCENS?

The medicine belongs to ATC group N02AJ13 – TRAMADOL A PARACETAMOL. Medicines with the same active substance can be found here.

Who manufactures ZALDIAR EFFERVESCENS?

STADA Arzneimittel AG, Bad Vilbel (D)

Is the medicine in shortage?

The latest report from the manufacturer is from 20. 5. 2025. Production was terminated with effect from 20. 5. 2025. The manufacturer lists medicines with the following code as a potential substitute: